EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Somatic mutational profiling identifies aggressive and indolent disease phenotypes in well-differentiated pancreatic neuroendocrine tumors

Leanne M Brown, Ryan A Hagenson, Jason M Sheltzer, John W Kunstman

Frontiers in Oncology · 08.05.2026 · 16

DOI: 10.3389/fonc.2026.1757796 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 08.05.2026. Verfasst von Leanne M Brown und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Yale School of Medicine, New Haven, CT, United States. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Integration of biomarkers into clinical management of well-differentiated pancreatic neuroendocrine tumors (PNETs) remains limited due to disease rarity and heterogeneity. By utilizing publicly available genomic databases, we’ve established a large cohort of well-differentiated PNETs for study, focusing on somatic mutations and disease subgroup stratification through a modified targeted sequencing approach.

Methods

A total of 434 patients, representing 310 primary tumors and 124 metastatic tumors, from nine publicly available genomic studies were included for study. A targeted sequencing panel consisting of 261 genes was applied across the cohort to establish somatic variant profiles for each patient. Patients were further allocated into established and novel molecular subgroups for additional investigation.

Results

MEN1 remains the most frequently mutated gene in both primary and metastatic tumors (41.9%, both). Within subgroup stratification, ATRX and DAXX mutations were not associated with a survival deficit in the metastatic setting, contrary to prior reports. TP53 mutations, traditionally associated with neuroendocrine carcinoma, remained prevalent occurring in 5.5% and 19.4% of primary and metastatic tumors, respectively. An additional 4.2% of primary tumors and 9.7% of metastatic tumors harbor mutations in either KRAS or SMAD4 that are more typically associated with pancreatic adenocarcinoma. TP53 mutations were associated with metastasis, suggesting the presence of a more aggressive disease phenotype.

Discussion

Somatic variants serve as prognostic biomarkers in well-differentiated PNETs. Profiling of TP53 , KRAS , or SMAD4 status may aid in identifying aggressive subtypes of disease. Additional evaluation of the utility of targeted tumor sequencing to guide PNET treatment is warranted.

Schlagwörter

Stichwörter der Autor:innen

PNETTP53 mutantaggressive diseasebiomarkerpancreatic neuroendocrine tumor

Autor:innen und Institutionen

  • Department of Surgery, Yale School of Medicine, New Haven, CT, United States.
  • Department of Radiation Oncology, Stanford School of Medicine, Palo Alto, CA, United States.

Zitieren

APA

Brown, L. M., Hagenson, R. A., Sheltzer, J. M., & Kunstman, J. W. (2026). Somatic mutational profiling identifies aggressive and indolent disease phenotypes in well-differentiated pancreatic neuroendocrine tumors. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1757796

Vancouver

Brown LM, Hagenson RA, Sheltzer JM, Kunstman JW. Somatic mutational profiling identifies aggressive and indolent disease phenotypes in well-differentiated pancreatic neuroendocrine tumors. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1757796

BibTeX
@article{Brown2026,
  author = {Brown, Leanne M and Hagenson, Ryan A and Sheltzer, Jason M and Kunstman, John W},
  title = {Somatic mutational profiling identifies aggressive and indolent disease phenotypes in well-differentiated pancreatic neuroendocrine tumors},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1757796}
}
Kostenlos starten →